Disparities in Guideline-Concordant Initial Systemic Treatment in Women with HER2-Negative Metastatic Breast Cancer: A SEER-Medicare Analysis

References

• LuJ, SteegPS, PriceJE, et al. Breast cancer metastasis: challenges and opportunities. Cancer Res. 2009;69(12):4951–4953. doi:10.1158/0008-5472.CAN-09-009919470768
   PubMedGoogle Scholar
• BonottoM, GerratanaL, PolettoE, et al. Measures of outcome in metastatic breast cancer: insights from a real-world scenario. Oncol. 2014;19(6):608–615. doi:10.1634/theoncologist.2014-0002
   Google Scholar
• KielyBE, SoonYY, TattersallMHN, StocklerMR. How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials. J Clin Oncol. 2011;29(4):456–463. doi:10.1200/JCO.2010.30.217421189397
   PubMed Web of Science ®Google Scholar
• PressDJ, MillerME, LiederbachE, YaoK, HuoD. De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype. Clin Exp Metastasis. 2017;34(8):457–465. doi:10.1007/s10585-017-9871-929288366
   PubMed Web of Science ®Google Scholar
• PartridgeAH, RumbleRB, CareyLA, et al. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of clinical oncology clinical practice guideline. J Clin Oncol. 2014;32(29):3307–3329. doi:10.1200/JCO.2014.56.747925185096
   PubMed Web of Science ®Google Scholar
• RocqueGB, WilliamsCP, JacksonBE, et al. Impact of nonconcordance with NCCN guidelines on resource utilization, costs, and mortality in de novo metastatic breast cancer. J Natl Compr Canc Netw. 2018;16(9):1084–1091. doi:10.6004/jnccn.2018.703630181420
   PubMed Web of Science ®Google Scholar
• LeMastersT, MadhavanSS, SambamoorthiU, et al. Receipt of guideline-concordant care among older women with stage I-III breast cancer: a population-based study. J Natl Compr Canc Netw. 2018;16(6):703–710. doi:10.6004/jnccn.2018.700429891521
   PubMed Web of Science ®Google Scholar
• CarlsonRW, AllredDC, AndersonBO, et al. Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012;10(7):821–829. doi:10.6004/jnccn.2012.008622773798
   PubMed Web of Science ®Google Scholar
• PoorvuPD, Vaz-LuisI, FreedmanRA, et al. Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States. Breast Cancer Res Treat. 2018;168(3):727–737. doi:10.1007/s10549-018-4659-429332137
   PubMed Web of Science ®Google Scholar
• ParisiM, PelletierC, CherepanovD, BroderMS. Outcomes research examining treatments, quality of life and costs in HER2-negative and triple-negative metastatic breast cancer: a systematic literature review. J Comp Eff Res. 2018;7(1):67–83. doi:10.2217/cer-2017-002729303361
   PubMed Web of Science ®Google Scholar
• KarnofskyDA, BurchernalJH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeodCM, editor. Evaluation of Chemotherapeutic Agents. Columbia University Press; 1949:191–205.
   Google Scholar
• American Cancer Society. Cancer facts and figures 2019. American Cancer Society, Atlanta, GA; 2019. Available from:https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf. Accessed 712, 2020.
   Google Scholar
• WarrenJL, KlabundeCN, SchragD, et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(8 Suppl):IV-3–18.
   Web of Science ®Google Scholar
• National Cancer Institute, Division of Cancer Control & Population Sciences. SEER-Medicare: about the data files. Available from:https://healthcaredelivery.cancer.gov/seermedicare/aboutdata/. Accessed 312, 2020.
   Google Scholar
• U.S. Health Resources and Services Administration. Bureau of health professions. Area resource file, 2009–2010 Release; 2010. Rockville, MD: US Department of Health and Human Services; Fairfax, VA: Quality Resource Systems, Inc. Codebook: HE-001(2010). Available from: https://data.hrsa.gov/topics/health-workforce/ahrf. Accessed 325, 2021.
   Google Scholar
• GrardisharWJ, AndersonBO, BlairSL, et al. Breast cancer version 3.2014. J Natl Compr Canc Netw. 2014;12(4):542–590. doi:10.6004/jnccn.2014.005824717572
   PubMed Web of Science ®Google Scholar
• ThariaultRL, CarlsonRW, AllredC, et al. Breast cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2013;11(7):753–760. doi:10.6004/jnccn.2013.009823847214
   PubMed Web of Science ®Google Scholar
• CarlsonRW, AllredDC, AndersonBO, et al. Breast cancer, version 1.2010, NCCN clinical practice guidelines in oncology. Obtained from the NCCN in January 2018. Available from:www.nccn.org. Accessed 325, 2021.
   Google Scholar
• CarlsonRW, AllredC, AndersonBO, et al. Breast cancer, version 1.2011, NCCN clinical practice guidelines in oncology. Obtained from the NCCN in January 2018. Available from:www.nccn.org. Accessed 325, 2021.
   Google Scholar
• AndersenR, NewmanJF. Societal and individual determinants of medical care utilization in the United States. Milbank Mem Fund Q Health Soc. 1973;51(1):95–124. doi:10.2307/33496134198894
   PubMedGoogle Scholar
• AndersenRM. Revisiting the behavioral model and access to medical care: does it matter?J Health Soc Behav. 1995;36(1):1–10. doi:10.2307/21372847738325
   PubMed Web of Science ®Google Scholar
• KlabundeCN, PotoskyAL, LeglerJM, WarrenJL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53(12):1258–1267. doi:10.1016/S0895-4356(00)00256-011146273
   PubMed Web of Science ®Google Scholar
• National cancer institute. SEER-Medicare: calculation of comorbidity weights; 2013. Available from:http://healthservices.cancer.gov/seermedicare/program/comorbidity.html.Accessed 321, 2020.
   Google Scholar
• CharlsonME, PompeiP, AlesKL, MacKenzieCR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi:10.1016/0021-9681(87)90171-83558716
   PubMedGoogle Scholar
• OnukwughaE, QiR, JayasekeraJ, ZhouS. Cost prediction using a survival grouping algorithm: an application to incident prostate cancer cases. Pharmacoeconomics. 2016;34(2):207–216. doi:10.1007/s40273-015-0368-626714688
   PubMed Web of Science ®Google Scholar
• AccordinoMK, WrightJD, VasanS, et al. Use and costs of disease monitoring in women with metastatic breast cancer. J Clin Oncol. 2016;34(24):2820–2826. doi:10.1200/JCO.2016.66.631327161970
   PubMed Web of Science ®Google Scholar
• LobbezooDJA, van KampenRJW, VoogdAC, et al. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome. Breast Cancer Res Treat. 2013;141(3):507–514. doi:10.1007/s10549-013-2711-y24104881
   PubMed Web of Science ®Google Scholar
• FairlieRW. An extension of the blinder-oaxaca decomposition technique to logit and probit models. J Econ Soc Meas. 2005;30(4):305–316. doi:10.3233/JEM-2005-0259
   Google Scholar
• AlyA, ShahR, HillK, BottemanMF. Overall survival, costs and healthcare resource use by number of regimens received in elderly patients with newly diagnosed metastatic triple-negative breast cancer. Future Oncol. 2019;15(9):1007–1020. doi:10.2217/fon-2018-040730717602
   PubMed Web of Science ®Google Scholar
• PalSK, ChildsBH, PegramM. Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat. 2011;125(3):627–636. doi:10.1007/s10549-010-1293-121161370
   PubMed Web of Science ®Google Scholar
• StoverDG, WinerEP. Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer. Breast. 2015;24:S132–S135. doi:10.1016/j.breast.2015.07.03226255198
   PubMed Web of Science ®Google Scholar
• PalleschiM, MaltoniR, SartiS, MelegariE, BravacciniS, RoccaA. Immunotherapy: the end of the “dark age” for metastatic triple-negative breast cancer?Breast J. 2019. doi:10.1111/tbj.13662
   Web of Science ®Google Scholar
• RakhaEA, El-SayedME, GreenAR, LeeAH, RobertsonJF, EllisIO. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109(1):25–32. doi:10.1002/cncr.2238117146782
   PubMed Web of Science ®Google Scholar
• ClarkO, BotrelTE, PaladiniL, FerreiraMB. Targeted therapy in triple-negative metastatic breast cancer: a systematic review and meta-analysis. Core Evid. 2014;9:1–11. doi:10.2147/CE.S5219724476748
   PubMedGoogle Scholar
• SchmidP, AdamsS, RugoHS, SchneeweissA. Impassion 130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC). J Clin Oncol. 2019;37(15_suppl):1003.
   Web of Science ®Google Scholar
• SchmidP, AdamsS, RugoHS, SchneeweissA. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–2121. doi:10.1056/NEJMoa180961530345906
   PubMed Web of Science ®Google Scholar
• DentR, TrudeauM, PritchardKI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15):4429–4434. doi:10.1158/1078-0432.CCR-06-304517671126
   PubMed Web of Science ®Google Scholar
• KriegerN. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health. 1992;82(5):703–710. doi:10.2105/AJPH.82.5.7031566949
   PubMed Web of Science ®Google Scholar